# Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia

> **NCT03817502** · PHASE3 · RECRUITING · sponsor: **Gedeon Richter Plc.** · enrollment: 330 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Cariprazine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03817502
- **Lead sponsor:** Gedeon Richter Plc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-06-06
- **Primary completion:** 2026-12-15
- **Final completion:** 2026-12-15
- **Target enrollment:** 330 (ESTIMATED)
- **Last updated:** 2025-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03817502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03817502, "Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT03817502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*